NUWELLIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.18 USD | -12.62% |
|
+7.27% | -69.01% |
| May. 02 | Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology | CI |
| Apr. 29 | Maxim Downgrades Nuwellis to Hold | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4.025 | 19.07 | 12.01 | 5.568 | 1.896 | 2.74 | - |
| Enterprise Value (EV) 1 | 4.025 | 19.07 | 12.01 | 5.568 | 1.896 | 2.74 | 2.74 |
| P/E ratio | -0.09 x | -0.65 x | -0.4 x | -0.13 x | -0.05 x | -0.1 x | -0.37 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.73 x | 2.56 x | 1.52 x | 0.65 x | 0.21 x | 0.27 x | 0.23 x |
| EV / Revenue | 0.73 x | 2.56 x | 1.52 x | 0.65 x | 0.21 x | 0.27 x | 0.23 x |
| EV / EBITDA | - | - | -630,994 x | -349,380 x | -114,222 x | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1.56 | 27.4 | 105 | 519 | 3,264 | 15,221 | - |
| Reference price 2 | 2,584 | 697.0 | 114.0 | 10.72 | 0.5809 | 0.1800 | 0.1800 |
| Announcement Date | 3/3/20 | 3/2/21 | 3/1/22 | 2/28/23 | 3/5/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.511 | 7.441 | 7.921 | 8.543 | 8.864 | 10.16 | 11.78 |
| EBITDA | - | - | -19.04 | -15.94 | -16.6 | - | - |
| EBIT 1 | -18.11 | -17.03 | -19.53 | -17.17 | -17.63 | -13.45 | -12.94 |
| Operating Margin | -328.54% | -228.84% | -246.51% | -200.99% | -198.89% | -132.38% | -109.79% |
| Earnings before Tax (EBT) 1 | -18.11 | -15.83 | -19.57 | -14.52 | -20.2 | -13.45 | -12.94 |
| Net income 1 | -18.11 | -15.84 | -19.58 | -14.52 | -22.63 | -19.95 | -16.94 |
| Net margin | -328.69% | -212.82% | -247.17% | -170.02% | -255.27% | -196.37% | -143.74% |
| EPS 2 | -27,900 | -1,067 | -287.0 | -83.55 | -11.52 | -1.770 | -0.4900 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 3/2/21 | 3/1/22 | 2/28/23 | 3/5/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.853 | 1.642 | 1.926 | 2.213 | 2.065 | 2.339 | 1.826 | 2.075 | 2.412 | 2.551 | 2.001 | 2.386 | 2.761 | 3.01 |
| EBITDA | -5.124 | -4.226 | -4.311 | -4.2 | -3.825 | -4.298 | -5.584 | -4.742 | -2.945 | -3.327 | - | - | - | - |
| EBIT 1 | -5.251 | -4.331 | -4.416 | -4.301 | -3.92 | -4.534 | -5.851 | -5.022 | -3.164 | -3.593 | -3.871 | -3.313 | -3.097 | -3.166 |
| Operating Margin | -283.38% | -263.76% | -229.28% | -194.35% | -189.83% | -193.84% | -320.43% | -242.02% | -131.18% | -140.85% | -193.45% | -138.85% | -112.17% | -105.18% |
| Earnings before Tax (EBT) 1 | -5.27 | -4.352 | -4.471 | -4.284 | -3.868 | -1.893 | -6.483 | -4.843 | -3.368 | -5.507 | -3.871 | -3.313 | -3.097 | -3.166 |
| Net income 1 | -5.272 | -4.354 | -4.473 | -4.286 | -3.87 | -1.896 | -6.485 | -4.845 | -3.37 | -7.927 | -5.871 | -4.813 | -4.597 | -4.666 |
| Net margin | -284.51% | -265.16% | -232.24% | -193.67% | -187.41% | -81.06% | -355.15% | -233.49% | -139.72% | -310.74% | -293.4% | -201.72% | -166.5% | -155.02% |
| EPS 2 | -75.00 | -41.00 | -42.00 | -41.00 | -37.00 | -5.000 | -5.760 | -3.650 | -1.810 | -2.240 | -1.060 | -0.3400 | -0.2100 | -0.1600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/1/22 | 5/10/22 | 8/9/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/5/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | 0.12 | 0.15 | - | - |
| Capex / Sales | - | - | - | 1.43% | 1.68% | - | - |
| Announcement Date | 3/3/20 | 3/2/21 | 3/1/22 | 2/28/23 | 3/5/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.18
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.01% | 2.74M | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| +26.03% | 107B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B |
- Stock Market
- Equities
- NUWE Stock
- Financials Nuwellis, Inc.
